New Treatment Options for Attention-Deficit/Hyperactivity Disorder (ADHD): Part I. Transdermal Methylphenidate and Lisdexamfetamine

Authors and Disclosures

Contributing Editor: Marcia L. Buck, PharmD, FCCP
Editorial Board: Kristi N. Hofer, PharmD and Michelle W. McCarthy, PharmD

Sidebar: Pharmacology Literature Review

Indomethacin pharmacokinetics and outcomes The authors of this study developed a population pharmacokinetic model for oral and intravenous indomethacin for the treatment of patent ductus arteriosus in preterm infants. The model was created from 227 serum concentrations from 90 infants given 0.01 mg/kg doses each day for 6 days. The mean estimate for clearance was 18.9 mL/hr/kg, with an estimated mean volume of distribution of 0.5 L/kg and half-life of 20 hours. Ductus closure occurred in 67% of patients. The authors reported no dose-response relationship between indomethacin plasma concentrations and ductus closure. Al Za'abi M, Donovan T, Tudehope D, et al. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome. Ther Drug Monit 2007;29:807-14.

Formulary Update

The Pharmacy and Therapeutics Committee did not meet during February. The next meeting will be March 14, 2008.

Formulary Update

The Pharmacy and Therapeutics Committee did not meet during February. The next meeting will be March 14, 2008.